PRM86 How to Select the Right Cost-Effectiveness Model? A Systematic Review and Stepwise Approach for Transferring an Existing Health Economic Model for Rheumatoid Arthritis  by van Haalen, H.G.M. et al.
A590  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
PRM87
ExtERnal Validation of thE SyREon diabEtES ModEl
Zsólyom A.1, Merész G.2, Nagyjánosi L.2, Nagyistók S.2, Nagy B.1, Kaló Z.1, Vokó Z.2
1Eötvös Loránd University, Budapest, Hungary, 2Syreon Research Institute, Budapest, Hungary
Objectives: The Syreon model was developed to predict the long term effects 
of screening, treatment and control of type 2 diabetes. After a successful internal 
validation the model’s outcomes needs to be compared to outcomes of cohorts that 
were not used for the modeling exercise. The objective of this study was to demon-
strate the methods and results of the external validation. MethOds: As a first step, 
we identified the applicable clinical trials and cohort studies which had not been 
used to build the model and simulated the patient cohorts for each study according 
to the published demographic, epidemiologic characteristics and treatment pat-
terns. The incidence rates of the predicted and observed outcomes were calculated 
for comparison and the results were evaluated using statistical methods and expert 
opinion. Results: 92 validation analyses were performed. The differences between 
the estimated and measured values of the incidences were within the range of 
44% and -100%. The slope of the fitted linear regression line was 0.5326 while the 
R2 value was 0.6956. The macular oedema submodel presented the best fit and the 
estimated values from the foot ulcer submodel had the lowest accuracy compared 
to values observed in other studies. cOnclusiOns: In overall the model performed 
well, however it frequently underestimated the incidence of the outcomes observed 
in the studies. This is most likely due to the limited information about the patient 
characteristics from the studies under evaluation. In most cases the information 
published about the population characteristics, treatment patterns and effective-
ness were not sufficiently detailed to precisely match the model’s input parameters. 
Without sufficient information average values were used as input parameters, and 
this way the model presumably simulated healthier patient cohorts than the ones 
participated in the studies.
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diSEntangling EffEctS on fatal and non-fatal caRdioVaSculaR 
EVEntS oVER tiME
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Objectives: Within acute coronary syndromes (ACS), the risk of experiencing fatal 
and non-fatal cardiac events is highest immediately after diagnosis and decreases 
over time. Visual inspection of survival curves from pivotal ACS trials suggest three 
potential risk periods. The highest risk (unstable disease) period typically lasts up to 
10 days from diagnosis. Patients then become more stable but are still at a high risk 
of events until approximately 30 days from diagnosis. Beyond 30 days patients are 
considered stable and at a lower risk of events. Different agents may be best suitable 
for different periods and may affect different events. The objective of this research is 
to estimate a model which enables the effects on fatal and non-fatal events follow-
ing an ACS episode to be disentangled and that distinguishes between periods of dis-
ease without accurately knowing how long these periods are. MethOds: A Markov 
model is estimated which distinguishes between three time periods and between 
fatal and non-fatal events. A likelihood function is derived as well as a Bayesian pro-
cedure to estimate the model parameters. The approach is tested using simulated 
data. Subsequently, event free survival data and overall survival data comparing 
ticagrelor with clopidogrel are taken from the Kaplan-Meier curves presented in the 
publication of the PLATO trial and model parameters are estimated based on these 
data. Results: Using simulated data the model mimics the data generating process 
perfectly and the approach seems quite powerful in distinguishing periods and dif-
ferences with patient numbers of 500 and above. cOnclusiOns: When applied to 
the PLATO study we conclude from the model that ticagrelor lowers the probability 
to experience an event in the unstable and stable high risk disease periods.
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Objectives: Emergence of long-term side effects of treating Parkinson’s disease 
(PD) patients with levodopa, particularly dyskinesia (levodopa induced dyskinesia - 
LID), limit the ability to optimally treat symptoms and consequences of PD. PD-LID 
interferes with performance of activities of daily living, ambulation and balance 
and increases health care costs. There are no approved treatments and no stud-
ies examining cost-effectiveness of an intervention for PD-LID. Objective of the 
present study is to develop a de-novo economic model to identify the value drivers 
for a drug to be cost-effective for treatment of PD-LID. MethOds: The model com-
bines a short-term (6 months) decision tree, to determine initial response to the 
drug, with a long-term Markov approach to model transition of patients across LID 
severity over lifetime. The model classifies LID severity using modified Abnormal 
Involuntary Movement scale (mAIMS) with disease states defined as mild (0-12), 
moderate (13-18) and severe (19-24). Disease state specific costs included costs 
of drug treatments, consultations/visits, paramedical services, laboratory tests, 
radiological examinations, hospitalizations, community/social services and 
unpaid services. State specific utilities were calculated and assigned based on 
literature. Results: The model suggests that initial response to the treatment, 
ability to improve and halt worsening dyskinesia health states are the greatest 
value drivers of the treatment for PD-LID. More than 90% of costs were driven 
by medical costs. A treatment for PD-LID that results in 6-month response rate 
of at least 50%, 25% increase in the probability of dyskinesia improving and 25% 
reduction in the probability of dyskinesia worsening results in a 0.28 QALY gain 
per patient. cOnclusiOns: This economic analysis suggests that a health care 
intervention that could improve the clinical parameters of dyskinesia can have 
significant beneficial impact on costs and utilities. Further studies are required 
vant chemotherapy (ACT). The collection and assessment of data inputs for a U.S. 
economic model evaluating this prognostic will be reported. MethOds: Medline 
and Tuft’s CEA Registry were searched for model parameters using the following 
terms and MeSH headings: NSCLC, adjuvant chemotherapy, recurrence, utilization, 
economics, cost, quality of life, utility, cost-effectiveness/-utility/-benefit. Inclusion 
criteria were randomized controlled trials (RCTs), meta-analyses, heath technology 
assessments, North American and European studies, quality of life analyses, and 
early lung cancer. Results were limited to full text and English articles. We also 
assessed relevant references listed in these articles. Results: The search yielded 
one meta-analysis and 7 RCTs assessing ACT in resected NSCLC. These studies 
report survival (HR 0.75-0.95 favoring ACT), ACT toxicity (30-85% experiencing grade 
3-4 toxicity), and stage distribution (Stage IA-7.6%, IB-29.9%, II-35.3%, III-27.2%). They 
also include disease free survival (HR 0.66-0.93 favoring ACT), but not stratified by 
NSCLC stage. Monthly cost of NSCLC was found in two studies (initial $5,255-11,496, 
continuing $2,602-3,733, terminal $9399-16,470). Two studies reported the U.S. cost of 
ACT toxicity ($4,629-9,516 per grade 3-4 event). Three studies reported utility values 
specific to early NSCLC including one with values related to ACT and toxicity with 
values varying from 0.60 to 0.75. Data reporting current U.S. ACT utilization was not 
identified. cOnclusiOns: Early NSCLC literature contains the majority of data 
inputs necessary for this model. Limitations exist, specifically regarding recurrence 
by stage, current ACT utilization and cost of health care resources. These limitations 
can be overcome using expert opinion, assumptions for guideline adherence and/
or conducting observational studies to inform the model.
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Objectives: Stroke–one of the leading causes of death and disability–represents 
substantial clinical and economic burden. Understanding treatment patterns and 
causative relations may help e.g. to identify outcomes predictors and cost driv-
ers. MethOds: We used Polish Hospital Stroke Registry data on patient baseline 
characteristics (demographics, risk factors, prestroke disability, stroke severity), 
hospital management, treatment outcomes and drugs (pre-admission, during hos-
pitalisation, and prescribed at discharge). We used inferred causation approach that 
deducts causal (not associative) interpretations from patterns of (conditional) inde-
pendence. In this primary analysis we used 5000 observations from 2007/2008 year, 
binary variables and assumed no hidden variables. We used Tetrad 4.3.10-6 with PC 
algorithm. Variables were grouped into five tiers, a priori forbidding some directions 
of causal influence. Large number of variables led us to a restrictive significance 
level (α = 0.0001). Results: New insight can be gained from existence, lack of, and 
the direction of causal relations. Our results: confirmed (without imposing prior 
knowledge) the use of cardiovascular drugs in relation with underlying risk factors 
and natural sequence of drug management (drugs used prior to, in acute stroke 
and at discharge); surprisingly suggested no causal relation between some clinical 
characteristics and drug use (e.g. history of stroke/diabetes and oral anticoagulants) 
or acute stroke treatment (e.g. aspirin, thrombolysis, stroke unit based treatment) 
and mortality/post-stroke disability; determined the causal direction between 
some risk factors (e.g hypertension and diabetes, gender and AF) or patient history 
and prestroke disability (history of stroke or age over 75 and impaired disability); 
could not unambiguously discover the causal-relation between stroke unit based 
treatment and unproven efficacy drugs use. cOnclusiOns: Apart from statistical 
or econometric approach, causal-type reasoning can be used both to confirm the 
intuition, and to detect new patterns in data. Further research should include the 
possibility of hidden variables and try to quantify the causal relations.
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Objectives: To a) to perform a systematic literature review to identify existing 
models for cost-effectiveness analysis of disease modifying anti rheumatic drugs 
in Rheumatoid Arthritis, and b) to develop and test a method for the selection of 
a model that is transferable to the Dutch health care setting by simple adapta-
tion. MethOds: We searched Medline and Embase to identify relevant studies in 
the English language between 1-1-2002 and 31-8-2012. For studies that met the 
inclusion criteria, we applied a 3-step approach in model selection. First, models 
that did not meet all minimal methodological requirements based on the OMERACT 
criteria were excluded. Second, the models were assessed based on their fit when 
transferred to the Dutch health care setting. Transferability factors as published by 
Welte et al., except for those that were deemed transferable by simple adaptation, 
were used for this ranking procedure. Finally, the remaining models underwent 
a general quality check using the Philips checklist. Models showing good fit and 
high quality were considered to be transferable to the Dutch health care setting 
using simple adaptation. Results: The systematic literature search resulted in 498 
papers, which included 33 unique health economic models. Only six models passed 
the OMERACT methodological requirements. Two of these models had imperfect 
transferability fit according to Welte. The remaining four models were, according 
to Philips, of good quality and were expected to be transferable by a simple adapta-
tion. cOnclusiOns: This study introduces a stepwise approach to the identifica-
tion and selection of health economic models that are transferable by a simple 
adaptation. This approach can be applied in various therapeutic areas, provided that 
the minimal methodological requirements are defined accordingly. Availability of 
health economic models coupled with structured model selection could improve 
the efficiency, quality and comparability of health economic evaluations.
